Slack Mark, Kirchhoff Christian, Moller Clemens, Winkler Dirk, Netzer Rainer
Evotec AG Schnackenburgallee 114 22525 Hamburg, Germany.
J Biomol Screen. 2006 Feb;11(1):57-64. doi: 10.1177/1087057105282712. Epub 2005 Nov 28.
A functional cell-based assay was developed using a generic proprietary assay protocol, based on a membrane-potential sensitive dye, for the identification of small-molecule antagonists against the Kv1.3 potassium ion channel. A high-throughput screen (HTS) was subsequently performed with 20,000 compounds from the Evotec library, preselected using known small molecule antagonists for both sodium and potassium ion channels. Following data analysis, the hit rate was measured at 1.72%, and subsequent dose-response analysis of selected hits showed a high hit confirmation rate yielding approximately 50 compounds with an apparent IC50 value lower than 10 microM. Subsequent electrophysiological characterization of selected hits confirmed the initial activity and potency of the identified hits on the Kv1.3 target and also selectivity toward Kv1.3 through measurements on HERG as well as Kv1.3-expressing cell lines. Follow-up structure-activity relationship analysis revealed a variety of different clusters distributed throughout the library as well as several singlicates. In comparison to known Kv1.3 blockers, new chemical entities and scaffolds showing potency and selectivity against the Kv1.3 ion channel were detected. In addition, a screening strategy for ion channel drug discovery HTS, medicinal chemistry, and electrophysiology is presented.
基于一种膜电位敏感染料,利用通用的专有检测方案开发了一种基于细胞的功能检测方法,用于鉴定针对Kv1.3钾离子通道的小分子拮抗剂。随后,使用来自Evotec文库的20000种化合物进行了高通量筛选(HTS),这些化合物是使用已知的钠和钾离子通道小分子拮抗剂预先筛选出来的。数据分析后,命中率为1.72%,对选定命中物的后续剂量反应分析显示,命中确认率很高,产生了约50种表观IC50值低于10 microM的化合物。对选定命中物的后续电生理表征证实了所鉴定命中物对Kv1.3靶点的初始活性和效力,以及通过对HERG以及表达Kv1.3的细胞系进行测量而对Kv1.3的选择性。后续的构效关系分析揭示了文库中分布的各种不同簇以及几个单独的化合物。与已知的Kv1.3阻滞剂相比,检测到了对Kv1.3离子通道具有效力和选择性的新化学实体和骨架。此外,还介绍了一种用于离子通道药物发现的高通量筛选、药物化学和电生理的筛选策略。